Michael Severino, M.D., is Executive Vice President, Chief Scientific Officer, where he leads the discovery, research and development of AbbVie therapies and is responsible for managing scientific partnerships and establishing research and development strategies for the company. Prior to joining AbbVie, Dr. Severino was Senior Vice President and Chief Medical Officer at Amgen, Inc. During his time at Amgen, he served in several leadership positions, including Vice President, Global Development; Vice President, Therapeutic Area Head, General Medicine and Inflammation Global Clinical Development; and Therapeutic Area Head, Inflammation Global Clinical Development. Dr. Severino has supervised broad therapeutic areas including oncology, inflammation, neuroscience and metabolic disorders. Prior to joining Amgen, he was Associate Director of Biologics Clinical Research at Merck & Co., Inc. Dr. Severino has published and presented extensively in areas such as genomics, virology, immunology and biologic chemistry. He serves on the board of directors of the Biotechnology Industry Organization (BIO) and is a member of its Regulatory Environment and Health Section Governing Board Committees. He earned a bachelor’s degree in biochemistry from the University of Maryland, College Park and a doctorate in medicine from The Johns Hopkins University in Baltimore. Dr. Severino completed research and post-doctoral training at Massachusetts General Hospital and Harvard Medical School in Boston, serving as Research Fellow for the Infectious Disease Unit/AIDS Research Center, Clinical Fellow for the Infectious Disease Unit and completing his residency in Internal Medicine. He is certified by the American Board of Internal Medicine.